| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lumiliximab | lymphocyte ige receptor | NA | Clinical trial target | TTD , DGIDB | Asthma[MeSHID:D001249] leukemia[MeSHID:D007938] Lymph[MeSHID:D008196] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
254.61 | phase 2 | unknown |
| lumiliximab | low affinity immunoglobulin epsilon fc receptor | biotech | NA | drugbank , DGIDB | Asthma[MeSHID:D001249] leukemia[MeSHID:D007938] Lymph[MeSHID:D008196] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
254.61 | investigational | unknown |
| lumiliximab | lymphocyte ige receptor | NA | Clinical trial target | TTD , DGIDB | Asthma[MeSHID:D001249] leukemia[MeSHID:D007938] Lymph[MeSHID:D008196] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
254.61 | phase 2 | antagonist |
| lumiliximab | low affinity immunoglobulin epsilon fc receptor | biotech | NA | drugbank , DGIDB | Asthma[MeSHID:D001249] leukemia[MeSHID:D007938] Lymph[MeSHID:D008196] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
254.61 | investigational | antagonist |
| click here to return to the previous page | ||||||||